Important matters:
Venture Group Holdings (02221) plans to issue a total of about 148.949 million shares at a premium of 78.51% to acquire 70% of Anhui Boiling Point Environmental Protection Technology Co., Ltd.
Xuanzhu Bio-B (02575) and INNOBIC reached a commercial cooperation on piroxil in the Thai market
Fosun Pharmaceuticals (02196): New indications for ruvometinib tablets received registration approval
Jingneng Clean Energy (00579): Jingxi Power increased capital to Jingxi Gas Thermal Power with about 280 million yuan of land use rights
Hengrui Pharmaceutical (01276): SHR-1819 injectable drug marketing license application accepted
Extreme Vision (06636) signs investment management agreement with CSAM
Xiansheng Pharmaceutical (02096): Yingmule® was approved by the State Drug Administration for listing in China
China Biopharmaceutical (01177): TQB6426 “GPC3 ADC” clinical trial application approved by FDA
Fubo Group (03738) signed a strategic partnership and commercial agreement with UNN to obtain 25 megawatts of data center capacity to build an “AI factory”
Genting Xinyao (01952): The marketing application for a new drug for treating acute episodes of paroxysmal supraventricular tachycardia in adults converted to sinus rhythm was approved in China
Kangzhe Pharmaceutical (00867): Innovative drug rucotinib phosphate cream Belutuo® increases atopic dermatitis indications (AD) application approved for marketing in China
Kingsley Biotech (01548) plans to split Bobobio and independently list it on the main board of the Stock Exchange
Operating performance:
Digitong Telecom (00315) announces annual results, profit attributable to shareholders of HK$525 million increased 10% year-on-year
The total cumulative contract sales for the first 8 months of Jindi Commercial Trading (00535) was about 4.408 billion yuan, a year-on-year decrease of 41.9%
Shenzhen Expressway Co., Ltd. (00548): Outer Ring Road Project toll revenue of 111 million yuan in July